Neuroendocrine Tumors

Any Differentiation
- Locally Advanced, 2nd line +

Well Differentiated
- Anti-proliferative
  - ECOG-ACRIN-EA2142
    - Phase II
    - Cisplatin & Etoposide vs Temozolomide & Capecitabine in Gastroenteropancreatic Neuroendocrine Ca
    - PI: Kunz ECOG-ACRIN
  - NET0024
    - Phases I
    - XmAb®L8087 in Advanced Neuroendocrine and Gastrointestinal Stromal Tumors
    - PI: Kunz Pending 2nd Priority

Poorly Differentiated
- VEO-ACRIN-
  - Phase II
  - RRx-001 in SCLC / NSCLC / Neuroendocrine Carcinoma or Ovarian Cancer (Including MDM2+)
  - PI: Padda EpicentRx, Inc

Liver-Dominant Metastatic Disease
- HEP0057
  - Phase III
  - Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver
  - PI: Kothary University of Pennsylvania

Other Trials
- VAR0149
  - Phase Ib/II
  - Hu5F9-G4 in Combination w/ Cetuximab in Solid Tumors & Advanced Colorectal Cancer
  - PI: Fisher Forty Seven Inc
- GI0012
  - Phase I
  - Personalized Live Attenuated Double Deleted Listeria Monocytogenes Immunotox in Colorectal Cancer
  - PI: Fisher Aduro Biotech Inc
- ECOG-ACRIN-EA2161
  - Phase II
  - MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)
  - PI: Fisher ECOG-ACRIN

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold